Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple topical therapy for Irvine-Gass syndrome after cataract surgery
IRCT20210519051344N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorzolamide, ketorolac and prednisolone in cystoid macular edema (CME) and Irvine-Gass syndrome (IGS), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Central macular thickness at 8 weeks. Started Jun 2021; status: completed.
02
Drugs
dorzolamideketorolacprednisolone
03
Conditions
cystoid macular edema (CME)Irvine-Gass syndrome (IGS)
Beyond the preview
Go deeper on IRCT20210519051344N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210519051344N1.